Ultra-late response (> 24 weeks) to anti-CGRP monoclonal antibodies in migraine: a multicenter, prospective, observational study
Sign Up to like & getrecommendations! Published in 2024 at "Journal of Neurology"
DOI: 10.1007/s00415-023-12103-4
Abstract: Nearly 60% of migraine patients treated with monoclonal antibodies (mAbs) targeting the calcitonin gene-related peptide (CGRP) pathway experience a ≥ 50% reduction in monthly migraine days (MMD) at 12 weeks compared to baseline (responders). However, approximately half… read more here.
Keywords: anti cgrp; cgrp mabs; late responders; response ... See more keywords
Repurposed versus disease-specific medicinals for the prophylaxis of migraine: an updated systematic review.
Sign Up to like & getrecommendations! Published in 2025 at "Pain management"
DOI: 10.1080/17581869.2025.2509474
Abstract: BACKGROUND Gepants, selective antagonists of the calcitonin gene-related peptide (CGRP) receptor, and monoclonal antibodies targeting CGRP or its receptor (anti-CGRP mAbs) are promising migraine treatments, demonstrating superior tolerability than traditional preventives. While their efficacy over… read more here.
Keywords: benefit risk; anti cgrp; cgrp mabs; migraine ... See more keywords
No additional benefit with detoxification strategies: A real world experience in 200 patients with chronic migraine and either simple or complex MOH treated with CGRP monoclonal antibodies
Sign Up to like & getrecommendations! Published in 2025 at "Cephalalgia"
DOI: 10.1177/03331024251329808
Abstract: Background Although withdrawal from analgesics with or without detoxification strategy represented a mainstay in medication overuse headache (MOH) management, recent evidence supports that it is no longer beneficial when CGRP-targeting monoclonal antibodies (CGRP-mAbs) are employed.… read more here.
Keywords: moh; cgrp mabs; complex moh; detoxification ... See more keywords
The clinical outcome of patients starting monoclonal antibodies anti-CGRP with concomitant migraine preventive treatments
Sign Up to like & getrecommendations! Published in 2025 at "Cephalalgia"
DOI: 10.1177/03331024251378776
Abstract: Background The management and role of standard preventive treatments (SPTs) in patients co-treated with monoclonal antibodies (mAbs) directed towards calcitonin gene-related peptide (CGRP) has been poorly investigated. The present study aimed to prospectively compare the… read more here.
Keywords: concomitant spts; cgrp; anti cgrp; cgrp mabs ... See more keywords
Anti-Calcitonin Gene-Related Peptide Monoclonal Antibodies in the Treatment of Patients With Concussion
Sign Up to like & getrecommendations! Published in 2022 at "Neurology"
DOI: 10.1212/01.wnl.0000801812.93958.f8
Abstract: Objective Investigate the efficacy of 3 anti-Calcitonin Gene-Related Peptide monoclonal antibodies (anti-CGRP mAbs), fremanezumab, galcanezumab, and erenumab, in concussion patients with post-traumatic headache (PTH) with a migraine phenotype. Background A study using monoclonal antibodies in… read more here.
Keywords: headache; cgrp mabs; treatment; anti cgrp ... See more keywords
Late Response to Anti-CGRP Monoclonal Antibodies in Migraine: A Multicenter, Prospective, Observational Study.
Sign Up to like & getrecommendations! Published in 2023 at "Neurology"
DOI: 10.1212/wnl.0000000000207292
Abstract: OBJECTIVES To assess frequency and characteristics of late responders (>12 weeks) to monoclonal antibodies (mAbs) targeting the calcitonin gene-related peptide (CGRP). METHODS This is a multicenter (n=16), prospective, real-life study, considering all consecutive adults with… read more here.
Keywords: multicenter prospective; cgrp mabs; late responders; monoclonal antibodies ... See more keywords
Cortical Thickness Changes in Migraine Patients Treated with Anti-Calcitonin Gene-Related Peptide Monoclonal Antibodies: A Prospective Age- and Sex-Matched Controlled Study
Sign Up to like & getrecommendations! Published in 2025 at "Biomedicines"
DOI: 10.3390/biomedicines13051150
Abstract: Background: Migraine is associated with structural brain abnormalities, including cortical thickness changes. Anti-calcitonin gene-related peptide monoclonal antibodies (anti-CGRP mAbs) are a novel therapy for migraine prevention, but their effects on cortical structures are poorly understood.… read more here.
Keywords: treatment; anti cgrp; cgrp mabs; thickness changes ... See more keywords
Pooled Analysis of Real-World Evidence Supports Anti-CGRP mAbs and OnabotulinumtoxinA Combined Trial in Chronic Migraine
Sign Up to like & getrecommendations! Published in 2022 at "Toxins"
DOI: 10.3390/toxins14080529
Abstract: OnabotulinumtoxinA, targeting the CGRP machinery, has been approved for the last two decades for chronic migraine prevention. The recently approved monoclonal antibodies (mAbs) directed towards the calcitonin gene-related peptide (CGRP) pathway open a new age… read more here.
Keywords: mabs onabotulinumtoxina; cgrp mabs; chronic migraine; evidence ... See more keywords